✦ LIBER ✦

A Phase I/II Trial Evaluating the Use of a Histone Deacetylase Inhibitor LBH589 in Addition to Corticosteroids in Patients with Acute Graft Versus Host Disease

✍ Scribed by Perez, Lia Elena; Fernandez, Hugo; Tomblyn, Marcie; Locke, Frederick; Field, Teresa; Pidala, Joseph; Elmer, Erika; Beato, Francisca; Anasetti, Claudio

Book ID: 122742516
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 69 KB
Volume: 19
Category: Article
ISSN: 1083-8791
DOI: 10.1016/j.bbmt.2012.11.515

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

411 A phase I trial of the histone deace

411 A phase I trial of the histone deacetylase inhibitor panobinostat (LBH589) and epirubicin in patients with solid tumor malignancies

✍ A.P. Moore; S. Thomas; C.J. Ryan; T.M. Jahan; S.G. DuBois; J.K. Chan; K.T. Thurn 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 65 KB

Phase-1 study of siplizumab in the treat

Phase-1 study of siplizumab in the treatment of pediatric patients with at least grade II newly diagnosed acute graft-versus-host disease

✍ Joel A. Brochstein; Stephan Grupp; Harry Yang; Stanley R. Pillemer; Gregory P. G 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 498 KB

A Phase I/II study of the safety and eff

A Phase I/II study of the safety and efficacy of the addition of sirolimus to tacrolimus/methotrexate graft versus host disease prophylaxis after allogeneic haematopoietic cell transplantation in paediatric acute lymphoblastic leukaemia (ALL)

✍ Michael A. Pulsipher; Donna A. Wall; Michael Grimley; Rakesh K. Goyal; Kenneth M 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 213 KB

Prochymal Improves Response Rates In Pat

Prochymal Improves Response Rates In Patients With Steroid-Refractory Acute Graft Versus Host Disease (SR-GVHD) Involving The Liver And Gut: Results Of A Randomized, Placebo-Controlled, Multicenter Phase III Trial In GVHD

✍ P.J. Martin; J.P. Uberti; R.J. Soiffer; H. Klingemann; E.K. Waller; A.S. Daly; R 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 93 KB

Phase II Trial: The Combination of Tacro

Phase II Trial: The Combination of Tacrolimus, Sirolimus, and Rabbit Anti-Thymocyte Globulin (Thymoglobulin® Thymo) to Prevent Acute Graft-vs.-Host Disease (aGVHD) in Patients Receiving Unrelated Hematopoietic Stem Cell Transplantation (UHSCT)

✍ Z. Al-Kadhimi; Z. Gul; R. Rodriguez; W. Chen; A. Mitchell; M. Abidi; L. Ayash; A 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 56 KB